Alpelisib is a selective phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) inhibitor, which is effective in treating PIK3CA-mutated HCC by inhibiting the mitogen-activated kinase-like protein (MAPK) and AKT cascade response. Here, PIK3CA is linked to hepatocellular carcinoma.